NextPoint is a biotechnology company that is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA pathway. They are developing a new class of monotherapies for patients who will not benefit from PD-1/L inhibitors. Their team of proven drug developers is working to deliver a new class of monotherapies for patients who will not benefit from PD-1/L inhibitors.
However, they have recently announced that Axel Hoos, MD, PhD has joined NextPoint Therapeutics Board of Directors.
Location: United States, Massachusetts, Cambridge
Total raised: $122.5M
Investors 3
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | BioImpact ... | bioimpactc... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.02.2024 | Series B | $122.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 15.02.2024 | NextPoint Therapeutics Raises $42.5M; Closes $122.5M Series B Financing | NextPoint Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, raised $42.5M in Series B extension funding. The round, which br... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 10.01.2023 | NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs | - |
| - | NextPoint Therapeutics Closes $42.5 Million To Develop New Class Of Precision Oncology Therapeutics | NextPoint Therapeutics – a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway – announced the closing of a $42.5 million Extension to its Series B financing round... |
| - | NextPoint Therapeutics | “NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies.” |